Prelude Therapeutics, Inc. (PLRD) files for IPO.

The IPO of Prelude Therapeutics will take place on September 24, 2020. It is a biotechnological company that develops medicines that target chromatin function for the treatment of cancer and rare diseases. Using its core competence in cancer biology and medical chemistry together with its own method that does not depend on the target class or technological platform, Prelude Therapeutics has created effective, fully integrated drug discovery mechanism, that helps to identify biological targets and create NCE (new chemical entities), allowing to move quickly to clinical development.
 
The estimated valuation of the company after its IPO will be $685 million. Morgan Stanley, Goldman Sachs and BofA Securities are the IPO joint bookrunners.